We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Oxytocin
A nine-amino-acid hormone with two very different stories. As an IV drug (Pitocin/Syntocinon) it is an established, supervised hospital medicine for inducing/augmenting labor and controlling postpartum bleeding. As a grey-market intranasal 'love/bonding/trust' spray it is largely UNPROVEN — the largest, most rigorous autism RCT (Sikich 2021, NEJM) was negative on its primary outcome, and replication of the famous single-dose social effects has been poor.
Prescription medication — not a dietary supplement
Oxytocin is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Oxytocin doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 1985–2026.
Based on 991 studies · 82 meta-analyses · 852 RCTs
Confidence
High confidenceBy outcome
The popular intranasal social use scores low because the largest RCT (Sikich 2021, NEJM, n=290) was null and meta-analyses are mixed-to-weak; only supervised IV obstetric use is well-established.
888 randomised trials
86% were about Oxytocin in an audit of 50 of them
Every randomised or controlled trial of Oxytocin indexed in PubMed, not a hand-picked subset. Meta-analyses and systematic reviews are deliberately excluded from this count: most of them cover many compounds at once, so counting them would inflate it.
PubMed · as of Sep 2026
129 trials ongoing or recruiting · 556 completed on ClinicalTrials.gov
141 of the completed trials have posted results
Registered trials show research momentum for Oxytocin, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Nov 2026
Showing the 997 most recent of 1022 studies.
Oxytocin is a hypothalamic neuropeptide that acts both as a circulating hormone and as a central neuromodulator. The honest evidence picture splits sharply by use.
(1) Medical/obstetric use: intravenous oxytocin (Pitocin, Syntocinon) is a long-established, FDA-approved drug given under continuous monitoring to induce or augment labor and to prevent/treat postpartum haemorrhage via uterine contraction; it also drives the milk-ejection (let-down) reflex in lactation.
This use is real and supervised, but it is a hospital intervention with risks (uterine hyperstimulation, fetal heart-rate changes, rare uterine rupture, water intoxication/hyponatraemia from antidiuretic activity) — not something to self-administer.
(2) Intranasal behavioural/psychiatric use: after early single-dose studies suggested oxytocin nasal spray could increase trust (Kosfeld 2005, Nature) and social cognition, it was widely hyped as a 'love hormone' and marketed grey-market for bonding, social anxiety, and autism.
The rigorous follow-up has been largely disappointing. The landmark phase-2 NIH multisite RCT in 290 autistic children and adolescents (Sikich 2021, NEJM, 24 weeks) found NO significant benefit on its primary social-withdrawal outcome versus placebo.
Meta-analyses of repeated intranasal oxytocin in autism and schizophrenia are mixed-to-null: some report a small effect on isolated social-cognition sub-measures, but overall core-symptom benefit is weak, inconsistent, and not robust to publication bias and trial quality. Brain-imaging trust studies (e.g.
Baumgartner 2008) are mechanistically interesting but small. The overall evidence for the popular intranasal social/behavioural use is therefore emerging at best and substantially over-sold relative to the data.
Binds the oxytocin receptor (OXTR), a G-protein-coupled receptor. In the periphery this triggers uterine smooth-muscle contraction and mammary myoepithelial contraction (milk ejection); in the brain (amygdala, striatum, hypothalamus) it modulates social-salience and threat-processing circuits.
Intranasal oxytocin is proposed to dampen amygdala threat reactivity and bias attention toward social cues. fMRI work links it to reduced amygdala/midbrain activation during trust adaptation — but behavioural translation in patient RCTs has been weak.
The well-established peripheral action: dose-dependent uterine contraction (labor induction/augmentation, postpartum haemostasis) and triggering of the milk-ejection reflex during lactation.
How Oxytocin works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
IV oxytocin is used IN labor under continuous medical supervision — never self-administer. Do not use intranasal/grey-market oxytocin in pregnancy.
The largest, most rigorous RCT was negative; do not expect benefit from grey-market intranasal oxytocin. Discuss any interest with a clinician.
Oxytocin can affect blood pressure and sodium balance — medical use requires monitoring.
Severe hypertension has been reported when oxytocin is given with vasopressors; relevant to the medical IV setting.
Combined uterotonic use can cause uterine hyperstimulation — managed by clinicians in the obstetric setting.
Oxytocin's antidiuretic activity plus excess electrolyte-free fluid can cause water intoxication and hyponatraemia.
Tip: Contact your treating team about the symptom and follow the product-specific instructions. Do not reduce, split, stop or restart prescribed treatment solely to continue this experiment. Clinician titration and continuous monitoring.
Tip: Limit electrolyte-free fluids; monitor sodium
Tip: Reported with intranasal use; reduce/stop
Tip: Poorly characterised with intranasal use; discontinue if troublesome
Oxytocin has an evidence score of 4/10 — emerging evidence based on 1019 indexed studies, including 6 meta-analyses. A nine-amino-acid hormone with two very different stories. As an IV drug (Pitocin/Syntocinon) it is an established, supervised hospital medicine for inducing/augmenting labor and controlling postpartum bleeding. As a grey-market intranasal 'love/bonding/trust' spray it is largely UNPROVEN — the largest, most rigorous autism RCT (Sikich 2021, NEJM) was negative on its primary outcome, and replication of the famous single-dose social effects has been poor. Representative study: PMID 31032882.
Dosing for Oxytocin: No self-directed dose is recommended by SupStack. Medical IV oxytocin is titrated by clinicians under monitoring; intranasal doses used in research trials are typically 18-48 IU/day, but this use is investigational and not endorsed for self-administration. Individual needs vary, so check the right dose for you with a healthcare provider.
Timing is flexible for Oxytocin — consistent daily use matters more than the time of day. Research trials administer intranasal oxytocin once or twice daily (e.g.
Oxytocin should be used with caution — talk to a healthcare provider before taking it. Reported side effects include hyponatraemia / water intoxication (high-dose IV), uterine hyperstimulation / tachysystole (IV use), headache / nausea. How often they occur is not established for all of them. Use caution if any of these apply to you: Self-administration in pregnancy outside clinical supervision; Use of medical IV oxytocin except in a monitored hospital setting; Known hypersensitivity to oxytocin.
Omega-3
Probably helpsEssential fatty acids critical for brain health, mood regulation, and reducing inflammation throughout the body.
Magnesium
Mixed evidenceSupports 300+ enzymatic reactions — critical for sleep, stress response, muscle function, and cognitive health.
St. John's Wort
Likely helpsModulates serotonin, dopamine, and norepinephrine; studied for mood, with trials in mild-to-moderate depression comparing it to SSRIs — requires drug-interaction caution.
Ashwagandha
Likely helpsReduces cortisol and anxiety while improving sleep quality and physical recovery in stressed adults.
Explore: Best supplements for Focus, Memory & Mood
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 1,022 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research